Navigation Links
Industry Pioneer Joins Profectus BioSciences to Support Innovation in Therapeutic and Preventative Vaccines

Company appoints Dr. William Haseltine, PhD to its Board of Directors

BALTIMORE, Sept. 16 /PRNewswire/ -- Profectus BioSciences Inc., a biotechnology company that develops therapeutic and preventative technologies to reduce the morbidity and mortality of viral diseases, today announced the appointment of Dr. William Haseltine, PhD, to the company's board of directors. A seasoned expert in innovating life saving drugs and medical devices, Haseltine brings more than thirty years of expertise in science and business development.

Dr. Haseltine currently serves as president of the Haseltine Foundation for Medical Sciences and the Arts, a foundation that supports access to high quality health for the poor and middle class of developing countries. He is also the chairman of Haseltine Global Health, LLC, a company dedicated to developing life saving drugs and medical devices.

In addition to these positions, he serves as an advisor to CMEA, a venture capital company, the Reliance Innovation Council, India and to several other biotechnology and pharmaceutical companies. Collectively, Dr. Haseltine has founded nine successful biotechnology companies including Human Genome Sciences, Inc.

"Dr. Haseltine is one of the industry's most respected and talented individuals. His addition to our company is a tremendous testament to the things we are looking to accomplish as we proceed with the commercialization phase of our operations, and becoming the leading viral disease company," said Shawn Patrick O'Brien, president and CEO of Profectus BioSciences. "Dr. Haseltine will provide strategic insight in helping us enhance and expand our technologies."

Dr. Haseltine also has contributed to the academic community and is well known for his pioneering research on cancer, HIV/AIDS and genomics. As a professor at Harvard Medical School, he was founder and the chair of two academic research departments. Today, he is an adjunct professor at The Scripps Institute for Medical Research and the Institute of Chemical Engineering the University of Mumbai, India. He is chairman of the Board of the Berkeley Center for Synthetic Biology. Dr. Haseltine has published more than 200 manuscripts in peer reviewed journals and is the author of several books.

"This is a very exciting time for Profectus BioSciences," said Dr. Haseltine. "With its seasoned leadership and innovative technologies, the company is perfectly positioned to help improve those who are afflicted with viral diseases. I'm very enthused to be a part of an organization that has the resources and expertise to realize this incredible opportunity."

Aside from his professional expertise, Dr. Haseltine is also very active in public service. He is co-chair of the President's Council of the Cold Spring Harbor Laboratory, a member of the Advisory Board of the Global Coalition on HIV/AIDS and he is a governor of the New York Academy of Science. He is a member of the Executive Committee of the Brookings Institution, a member of the Council on Foreign Relations, and a member of the Chairman's Circle of the Asia Society. He is also a founder of the American Freedom Campaign.

About Profectus BioSciences Inc.

Profectus BioSciences Inc. began operations in early 2005 to develop and commercialize technologies to reduce the morbidity and mortality caused by human viral diseases, including the human immunodeficiency virus (HIV), the causative agent of AIDS. Founded to fulfill the mission of its co-founders Drs. Gallo, Blattner, and Redfield (collectively, the founders) for "bench-top-to-bedside" medicine, the Company applies its specific scientific expertise to help commercialize promising unique technologies used for human and animal health. For more information please visit:

SOURCE Profectus BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Friends of the Earth Report on Biofuel Production Offers Incomplete, Outdated and Inaccurate Picture, According to Brazilian Sugarcane Industry Association
2. Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts
3. Biotechnology & Drug Discovery Markets Push Up Demand for Lab Automation Products, According to a New Report by Global Industry Analysts
4. Protect Marylands Bioscience Industry
5. Progenitor Cell Therapy Secures Industry Accreditation
6. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
7. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
8. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
11. Nile Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, ... will participate in a fireside chat discussion at the ... New York . The discussion is scheduled for ... .  A replay will be available ... Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications and ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association (USGA) ... USGA Green Section Award. Presented annually since 1961, the USGA Green Section Award recognizes ... with turfgrass. , Clarke, of Iselin, N.J., is an extension specialist of ...
(Date:11/24/2015)... ... 24, 2015 , ... Copper is an essential micronutrient that ... proteins, copper is also toxic to cells. With a $1.3 million award from ... conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. aeruginosa), ...
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
Breaking Biology News(10 mins):